Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04554992 · ClinicalTrials.gov registry record · Phase 1
Convalescent Plasma for the Treatment of COVID-19 (Coronavirus Disease 2019)
A Phase 1 study, sponsored by The Methodist Hospital Research Institute.
- Completed
- Registry status
- Phase 1
- Development phase
- 350
- Enrollment target
NCT04554992 is a Phase 1 study that has completed, run by The Methodist Hospital Research Institute. The registered enrollment target is 350 participants.
The verdict
NCT04554992, a Phase 1 study, has completed, sponsored by The Methodist Hospital Research Institute.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 350 participants
- Enrollment target
Study Summary
This pilot, prospective study will assess the safety and efficacy of COVID-19 convalescent plasma versus standard care as treatment for severe and/or critical COVID-19 (as defined in the inclusion criteria) in adults 18 years of age and older. A total of 350 eligible subjects will receive a transfusion of anti-SARS-CoV2 ( severe acute respiratory syndrome) convalescent plasma.
Interventions
- BIOLOGICAL COVID 19 Convalescent Plasma
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 350 participants |
| Start Date | 2020-03-20 |
| Est. Completion | 2023-12-20 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04554992
The ClinicalTrials.gov registry entry for NCT04554992 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 350 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is The Methodist Hospital Research Institute, which has 126 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which COVID 19 Convalescent Plasma is the first listed.
NCT04554992 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04554992 about?
NCT04554992 is a clinical study titled "Convalescent Plasma for the Treatment of COVID-19 (Coronavirus Disease 2019)". This pilot, prospective study will assess the safety and efficacy of COVID-19 convalescent plasma versus standard care as treatment for severe and/or critical COVID-19 (as defined in the inclusion criteria) in adults 18 years of age and older. A total of 350 eligible subjects will receive a transfus...
What is the current status of trial NCT04554992?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 350 participants. The study started on 2020-03-20. Estimated completion is 2023-12-20.
What interventions are being tested in trial NCT04554992?
The interventions under investigation include: COVID 19 Convalescent Plasma (BIOLOGICAL).
Who is sponsoring clinical trial NCT04554992?
This trial is sponsored by The Methodist Hospital Research Institute, which has 126 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.